Published online before print July 24, 2006, doi: 10.1161/CIRCULATIONAHA.106.634089
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:381-387.)
© 2006 American Heart Association, Inc.
Epidemiology |
Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events
From the Donald W. Reynolds Center for Cardiovascular Research (S.M., J.E.B., P.M.R.), Leducq Center for Molecular and Genetic Epidemiology (S.M., P.M.R.), Center for Cardiovascular Disease Prevention (S.M., P.M.R.), Division of Preventive Medicine (S.M., J.E.B., P.M.R.), and Division of Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; Department of Epidemiology, Harvard School of Public Health, Boston, Mass (J.E.B., P.M.R.); and Department of Laboratory Medicine, Children’s Hospital and Harvard Medical School, Boston, Mass (N.R.).
Correspondence to Samia Mora, MD, MHS, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave E, Boston, MA 02215. E-mail smora2{at}partners.org
Received April 14, 2006; revision received May 22, 2006; accepted May 25, 2006.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Current guidelines suggest measuring high-sensitivity C-reactive protein (hs-CRP) as an aid to coronary risk assessment in adults without cardiovascular disease (CVD). Whether other inflammatory biomarkers, such as fibrinogen, add further prognostic information is uncertain.
Methods and Results— In a prospective study of 27 742 initially healthy middle-aged women, the associations of baseline immunoassay fibrinogen and hs-CRP measurements with incident CVD were examined over a 10-year follow-up period. Compared with women in the bottom biomarker quintile, age-adjusted hazard ratios (95% confidence intervals [CIs]) for incident CVD for quintiles 2 to 5 of fibrinogen were 1.10 (0.86 to 1.41), 1.30 (1.03 to 1.65), 1.46 (1.16 to 1.85), and 2.43 (1.95 to 3.02); for hs-CRP they were 1.48 (1.06 to 2.05), 1.70 (1.24 to 2.33), 2.20 (1.63 to 2.96), and 3.24 (2.43 to 4.31). After further adjustment for established risk factors, both biomarkers remained associated (P for trend 
0.001) with incident CVD (hazard ratio, 1.35; 95% CI, 1.07 to 1.71 for top fibrinogen quintile; and hazard ratio, 1.68; 95% CI, 1.22 to 2.29 for top hs-CRP quintile compared with the bottom quintiles). Further adjustment for the other biomarker resulted in hazard ratios of 1.23 and 1.56 (P for trend=0.02 and 0.002), respectively. Although fibrinogen correlated positively with hs-CRP (rs=0.41, P<0.001), the highest CVD risk was associated with elevated levels of both fibrinogen and hs-CRP: age-adjusted hazard ratio of 3.45 (95% CI, 2.60 to 4.57) for women with fibrinogen >393 mg/dL and hs-CRP >3 mg/L compared with <329 mg/dL and <1 mg/L, respectively.
Conclusions— In this cohort of initially healthy women, baseline levels of fibrinogen measured with a high-quality immunoassay provided additive value to hs-CRP and traditional risk factors in predicting incident CVD.
Key Words: acute-phase proteins • C-reactive protein • fibrinogen • inflammation • women
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Fibrinogen is a circulating glycoprotein that has long been known to be a nonspecific acute-phase reactant in addition to its important role as a clotting factor.1,2 Numerous studies have related fibrinogen levels to established cardiovascular risk factors, cardiovascular disease (CVD), and mortality.3–12 A recent meta-analysis from the Fibrinogen Studies Collaboration found moderate to strong associations with cardiovascular outcomes in a comprehensive analysis of 154 211 asymptomatic individuals from 31 prospective studies.13
Despite the evidence linking fibrinogen with CVD, recent guidelines from an expert panel from the Centers for Disease Control and Prevention/American Heart Association recommended against measuring fibrinogen or other acute-phase reactants, at the same time that they favored the use of high-sensitivity C-reactive protein (hs-CRP), as an aid for coronary risk assessment in the primary prevention of CVD.14 The main reasons cited against using fibrinogen are related to concerns about assay precision and accuracy due to the existence of a variety of methods (functional and mass-based assays) used for its measurement, resulting in substantial analytical variation and limiting efforts at assay standardization.14,15 Even if these assay considerations were to be overcome, it is unclear that measuring fibrinogen would provide additive value beyond that conferred by hs-CRP, given the positive correlation between inflammatory biomarkers.16
Clinical Perspective p 387
Therefore, this study was conducted to determine whether baseline fibrinogen levels, alone and in combination with hs-CRP, predict incident CVD in an asymptomatic cohort of women with the use of a reliable mass-based fibrinogen immunoassay that can be standardized and for which a World Health Organization calibrator is available.17 We hypothesized that the combined measurement of fibrinogen, by this high-quality immunoassay, and hs-CRP may have additive value for predicting CVD, potentially reflecting different pathophysiological aspects of atherothrombosis, namely, prothrombotic and proinflammatory pathways.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
Study participants were enrolled in the Women’s Health Study, a recently completed randomized, double-blinded, placebo-controlled clinical trial of low-dose aspirin and vitamin E in the primary prevention of CVD and cancer in US female healthcare professionals.18–20 Eligible participants were apparently healthy women, aged 45 years or older, who were free of self-reported CVD or cancer at study entry (1992–1995), with follow-up for incident CVD through February 2005. At the time of enrollment, participants gave written informed consent, completed questionnaires on demographics, medical history, medications, and lifestyle factors, and were asked to provide a blood sample. In total, 27 742 women with both fibrinogen and hs-CRP baseline measurements constituted the study population for this analysis. The study was approved by the institutional review boards of the Brigham and Women’s Hospital (Boston, Mass). The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Baseline Plasma Measurements
EDTA blood samples were obtained at the time of enrollment and stored in vapor phase liquid nitrogen (–170°C). Samples were thawed and analyzed in a core laboratory certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization Program. Fibrinogen was measured with an immunoturbidimetric assay, which is a mass-based assay with international standards (Kamiya Biomedical, Seattle, Wash).17 hs-CRP was measured with a high-sensitivity immunoturbidimetric assay on the Hitachi 917 autoanalyzer (Roche Diagnostics, Indianapolis, Ind), with the use of reagents and calibrators from Denka Seiken (Tokyo, Japan). The coefficients of variation obtained from blinded simultaneously analyzed quality controls were <5% for fibrinogen and <3% for CRP. Total, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol were assayed directly with reagents from Genzyme Corporation (Cambridge, Mass) and Roche Diagnostics (Indianapolis, Ind) with the use of a Hitachi 911 autoanalyzer.
Ascertainment of Incident Cardiovascular Events
Participants were followed up for the composite end point of incident CVD (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death). Medical records were obtained and reviewed for confirmation of events as previously described.21 Deaths from cardiovascular causes were confirmed by autopsy reports, death certificates, medical records, and contacts with family members.
Statistical Analyses
Statistical analyses were done with the use of STATA version 8.2 (StataCorp, College Station, Tex). First, we calculated Spearman rank correlation coefficients (rs) for continuous variables. Next, fibrinogen and hs-CRP were divided into quintiles on the basis of their distribution among women not taking hormone replacement, following guidelines from the Department of Health and Human Services for lipid standardization, and these quintile cut points were then applied to the rest of the cohort.22 Survival analysis was performed with the use of cumulative event curves, log-rank tests, and Cox proportional hazards regression models to adjust for covariables. The proportional hazard assumption was tested and satisfied with the use of Schoenfeld residuals.
To compare our results with prior studies, we first adjusted for age (years) and then further adjusted for race, smoking (never, past, current), systolic blood pressure, total and HDL cholesterol, diabetes mellitus, hormone use, and body mass index. In addition, models that excluded body mass index and diabetes were examined because the effect of these variables may involve the same pathway as the biomarkers. Alcohol consumption, physical activity, and educational status were not included in the final Cox regression models because none of these factors affected the findings. Subsequently, to test for potential confounding or effect mediation by the other biomarker, models examining the association of fibrinogen with CVD were further adjusted for hs-CRP and vice versa.
We then evaluated the joint associations of fibrinogen and hs-CRP with incident CVD by dividing participants into prespecified groups of high or low fibrinogen (greater than or less than or equal to top tertile among women not taking hormone therapy) and high or low hs-CRP (>3 or 3 mg/L) as well as based on 9 categories of fibrinogen tertiles and hs-CRP clinical cut points (<1, 1 to 3, and >3 mg/L).15 We also repeated this analysis of the joint association of hs-CRP and fibrinogen using hs-CRP tertiles instead of clinical cut points with essentially unchanged results, and hence these results were not shown.
Finally, statistical tests for interaction between fibrinogen tertiles and hs-CRP categories were obtained from age-adjusted Cox regression models. On an a priori basis, we also tested for interaction between fibrinogen and hs-CRP categories with each of smoking, obesity, diabetes, and postmenopausal state because these variables may predispose individuals to an inflammatory state. All reported probability values were 2-tailed, with <0.05 considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The study participants were middle-aged women at baseline (Table 1), with median (interquartile range [IQR]) fibrinogen levels of 351 (IQR, 308 to 403) mg/dL and median hs-CRP levels of 2.01 (IQR, 0.80 to 4.37) mg/L. Baseline prevalence of cardiovascular risk factors was positively associated with higher levels of fibrinogen. In particular, hs-CRP levels differed substantially by fibrinogen quintiles, with median hs-CRP values of 1.00 and 4.58 mg/L in the bottom and top fibrinogen quintiles, respectively (P for trend <0.001). When examined as continuous variables, fibrinogen was positively correlated with hs-CRP (rs=0.41, P<0.001) and showed small positive correlations with blood pressure, total and low-density lipoprotein cholesterol, and body mass index (rs=0.1 to 0.3) and a negative correlation with HDL cholesterol (rs=–0.23).
|
During a mean (±SD) follow-up of 9.9±1.3 years (274 083 person-years), there were 898 incident CVD events (3.3 per 1000 person-years). Cumulative event probabilities for incident CVD demonstrated similar divergence of the curves for fibrinogen quintiles compared with hs-CRP quintiles (Figure 1), with P<0.001 from log-rank tests of significance across quintiles of either biomarker. As shown in Tables 2 and 3
, both fibrinogen and hs-CRP were associated with incident CVD (age-adjusted hazard ratio, 2.43; 95% confidence interval [CI], 1.95 to 3.02 for top fibrinogen quintile; and age-adjusted hazard ratio, 3.24; 95% CI, 2.43 to 4.31 for top hs-CRP quintile; both compared with the bottom quintiles). Linear associations were seen for fibrinogen quintiles 2 to 4 as well as for hs-CRP quintiles 2 to 4. Per 1-g/L increase in baseline fibrinogen, the age-adjusted hazard ratio was 1.46 (95% CI, 1.37 to 1.55; P<0.001).
|
|
|
After adjustment for age, smoking, blood pressure, total and HDL cholesterol, diabetes, hormone use, and body mass index (Tables 2 and 3
), higher quintiles of both biomarkers remained associated with CVD (P for trend 0.001), with a hazard ratio for the top quintile of fibrinogen of 1.35 (95% CI, 1.07 to 1.71) and for hs-CRP of 1.68 (95% CI, 1.22 to 2.29). Adjustment for baseline use of antihypertensive and lipid-lowering medication resulted in hardly any change in the hazard ratios, nor did adjustment for randomization status to aspirin or vitamin E. Models that excluded diabetes and body mass index resulted in somewhat higher hazard ratios for fibrinogen (1.49; 95% CI, 1.19 to 1.87 for top versus bottom quintile) and hs-CRP (1.83; 95% CI, 1.35 to 2.47 for top versus bottom quintile).
In a Cox model that additionally adjusted fibrinogen for hs-CRP, the hazard ratio comparing the top and bottom quintiles of fibrinogen was somewhat attenuated to 1.23 (95% CI, 0.97 to 1.57), but the trend across quintiles remained significant (P for trend=0.02) (Table 2). Similarly, in a Cox model that adjusted hs-CRP for fibrinogen, the hazard ratio comparing the top and bottom quintiles of hs-CRP was also mildly attenuated to 1.56 (95% CI, 1.13 to 2.16), but the trend across quintiles remained significant (P for trend=0.002).
In joint analyses of fibrinogen and hs-CRP with incident CVD according to 4 prespecified groups of high and low fibrinogen or hs-CRP (Figure 2), the highest CVD event rates were significantly associated with high levels of both fibrinogen and hs-CRP, and the lowest rates were significantly associated with low levels of both biomarkers (P log-rank <0.001). Of note, women with high fibrinogen but low hs-CRP levels had similar event rates during follow-up compared with women who had low fibrinogen but high hs-CRP levels, with virtual overlap of the 2 event rate curves.
|
We then divided the participants into 9 categories on the basis of fibrinogen tertiles and hs-CRP clinical cut points (<1, 1 to 3, and >3 mg/L) according to guidelines.14 With the use of the referent group of women with the lowest fibrinogen and hs-CRP levels (fibrinogen <329 mg/dL and hs-CRP <1 mg/L), the age-adjusted hazard ratio for women with fibrinogen >393 mg/dL and hs-CRP >3 mg/L was 3.45 (95% CI, 2.60 to 4.57) (Figure 3). In comparison, when examined separately, the age-adjusted hazard ratios for high versus low levels of fibrinogen and hs-CRP, with the use of the above cut points, were 1.93 (95% CI, 1.63 to 2.29) and 2.27 (95% CI, 1.89 to 2.73), respectively. Participants with either top values for fibrinogen but bottom or intermediate values for hs-CRP, or top values for hs-CRP but bottom or intermediate values for fibrinogen, were at increased risk for CVD compared with women with bottom values for both biomarkers. When we used tertile cut points to define elevated levels of hs-CRP instead of clinical cut points, the results were essentially unchanged.
|
There was no evidence of multiplicative interaction between fibrinogen tertiles and hs-CRP categories for the outcome of incident CVD (P for interaction=0.24). In addition, there was no interaction between fibrinogen tertiles or hs-CRP categories with smoking, obesity, diabetes, or postmenopausal state. The association of fibrinogen and hs-CRP with incident total CVD was similar to that observed in analyses of the components of the composite end point.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this prospective study of 27 742 initially healthy women, we found significant associations for higher levels of immunoassay-measured fibrinogen and hs-CRP, alone and in combination, with incident CVD over a 10-year follow-up period. Despite the positive correlation between fibrinogen and hs-CRP, high levels of the 2 biomarkers together were associated with the highest CVD risk. The predictive value of fibrinogen was similar in magnitude and additive to that of hs-CRP, with a joint effect that was greater than the individual effect of either biomarker separately, without evidence of multiplicative interaction, with a 3-fold increased risk associated with having a fibrinogen level >393 mg/dL together with an hs-CRP level >3 mg/L compared with levels <329 mg/dL and <1 mg/L, respectively.
A number of epidemiological studies have examined the association of fibrinogen with CVD,1,3,5,23–27 but few have directly compared fibrinogen with hs-CRP or examined their joint association.24,25 In the Fibrinogen Studies Collaboration meta-analysis, adjustment for established risk factors and for CRP measurements in the subgroup of participants that had such measurements did not change the significant association found for fibrinogen with incident coronary events.13 The additive value of fibrinogen and hs-CRP that we found in our study, when fibrinogen was measured with a reliable and high-quality assay, suggests a complementary role for the 2 biomarkers in risk prediction that is not captured with standard risk factors or either biomarker individually. That the magnitude of predictive value in the women participants in this study was greater for hs-CRP than for fibrinogen is consistent with prior studies in men.9,28
In addition to its role as an inflammatory biomarker, fibrinogen is the predominant coagulation factor in blood plasma and plays an important role in platelet aggregation, fibrin formation, and plasma visosity.29,30 Our findings suggest that plasma fibrinogen levels may reflect both an inflammatory and a prothrombotic state because the risk associated with higher fibrinogen levels was only partially accounted for by higher hs-CRP levels. Attenuation of the risk associated with fibrinogen after adjustment for hs-CRP, and vice versa, may be explained by potential confounding, or possible mediation, of some of the effect of fibrinogen via inflammation. It is also possible that fibrinogen and hs-CRP may represent different aspects of an underlying inflammatory process with both biomarkers contributing CVD risk information.
Risk factors are known to act in concert in the development of CVD.31 It is possible that factors related to adiposity and insulin resistance, such as abdominal obesity, may also be contributing to the increased CVD risk associated with fibrinogen or hs-CRP, as suggested in our data with the attenuation of the hazard ratios after adjustment for body mass index and diabetes. Adipose tissue, particularly visceral adipose tissue, is known to be metabolically active and is associated with both a prothrombotic and a proinflammatory state, both of which may be reflected in higher plasma fibrinogen and hs-CRP levels.32–34
Potential limitations to our study include the single measurements of both fibrinogen and hs-CRP, such that we were unable to examine the value of repeated measurements of the biomarkers. However, a single measurement is likely to underestimate the magnitude of the association between the biomarkers and CVD. Although we adjusted for established cardiovascular risk factors as well as examined models that additionally adjusted for alcohol use, physical activity, and education, we cannot exclude the possibility that potential confounding by unmeasured factors may explain part of the additive value of fibrinogen for CVD risk prediction. Our study population was limited to women who were healthcare professionals and mostly white. Although our study design was prospective, there is no published randomized clinical trial to date examining the clinical value of inflammatory biomarkers in tailoring therapy in a primary prevention population, although such a study is ongoing.35
Strengths of our study include the reliable measurement of both fibrinogen and hs-CRP levels with high accuracy in a core laboratory. Currently available commercial assays for fibrinogen encompass a wide variety of assays, including functional clotting assays that are difficult to standardize and demonstrate substantial variability.36 In comparison, the mass-based immunoassay that was used in this study can be standardized with available calibrators from the World Health Organization.17 Another strength of this study is the well-characterized risk factor profile of the participants that allowed us to control for potential confounding. In addition, the large size and 10-year duration of follow-up allowed for the separate as well as joint examination of both biomarkers with respect to incident events.
In summary, immunoassay-measured fibrinogen and hs-CRP both contributed CVD risk information that was additive to the risk associated with the established risk factors and the other biomarker. Although both fibrinogen and hs-CRP were positively correlated, their combined effect provided CVD risk information that was greater than that provided by either biomarker separately, potentially reflecting different pathophysiological processes in the development of atherothrombotic events. Future studies are needed to further evaluate whether the use of a mass-based assay, similar to the immunoassay used in this study, may complement the use of hs-CRP and established risk factors for identifying high-risk individuals in other populations.
|
Acknowledgments |
|---|
The authors thank the investigators, staff, and participants of the Women’s Health Study for their valuable contributions.
Sources of Funding
The research for this article was supported by grants from the Donald W. Reynolds Foundation, Leducq Foundation, and Doris Duke Charitable Foundation and by philanthropic support from Elisabeth and Alan Doft and their family. The Women’s Health Study is supported by grants HL-43851 and CA-47988 from the National Heart, Lung, and Blood Institute and the National Cancer Institute. Dr Mora is supported by grant 0670007N from the American Heart Association. The funding agencies played no role in the design, conduct, data management, analysis, or manuscript preparation related to this manuscript.
Disclosures
Dr Ridker is listed as a coinventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in CVD. The other authors report no conflicts.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Eastham RD, Morgan EH. Plasma-fibrinogen levels in coronary-artery disease. Lancet. 1963; 41: 1196–1197.
2. Tracy RP. Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest. 2003; 124: 49S–57S.[CrossRef][Medline] [Order article via Infotrieve]
3. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980; 1: 1050–1054.[Medline] [Order article via Infotrieve]
4. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311: 501–505.[Abstract]
5. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987; 258: 1183–1186.
6. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation. 1991; 83: 836–844.
7. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997; 96: 1102–1108.
8. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med. 1999; 131: 376–86.
9. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol. 1999; 33: 1347–1352.
10. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999; 19: 1776–1783.
11. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost. 2000; 84: 553–558.[Medline] [Order article via Infotrieve]
12. Smith GD, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol. 2005; 25: 2228–2233.
13. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005; 294: 1799–1809.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499–511.
15. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, Catravas JD, Cole TG, Cooper GR, Khan BV, Kimberly MM, Stein EA, Taubert KA, Warnick GR, Waymack PP. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the Laboratory Science Discussion Group. Circulation. 2004; 110: e545–549.
16. Fortmann SP, Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, Pearson TA, Siscovick D, Vinicor F, Wilson PF. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the Population Science Discussion Group. Circulation. 2004; 110: e554–e559.
17. Whitton CM, Sands D, Hubbard AR, Gaffney PJ. A collaborative study to establish the 2nd International Standard for Fibrinogen, Plasma. Thromb Haemost. 2000; 84: 258–262.[Medline] [Order article via Infotrieve]
18. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293–1304.
19. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005; 294: 56–65.
20. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005; 294: 47–55.
21. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.
22. Hainline A, Karon J, Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. 2nd ed. Bethesda, Md: Department of Health and Human Services; 1982.
23. Folsom AR, Conlan MG, Davis CE, Wu KK, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol. 1992; 2: 481–494.[Medline] [Order article via Infotrieve]
24. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of C-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease: baseline findings of the PAIS project. Atherosclerosis. 2001; 156: 451–456.[CrossRef][Medline] [Order article via Infotrieve]
25. Lind P, Hedblad B, Stavenow L, Janzon L, Eriksson KF, Lindgarde F. Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. Arterioscler Thromb Vasc Biol. 2001; 21: 452–458.
26. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285: 2481–2485.
27. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol. 2002; 22: 1042–1045.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
29. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003; 290: 932–940.
30. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood. 2004; 103: 1728–1734.
31. Wilson PW. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation. 2004; 110: e568–e571.
32. Despres JP The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients’ risk. Obes Res. 1998; 6 (suppl 1): 8S–17S.[Medline] [Order article via Infotrieve]
33. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131–2135.
34. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002; 105: 2696–2698.
35. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER): can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006; 97: 33A–41A.[CrossRef][Medline] [Order article via Infotrieve]
36. Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation—performance and standardization: a background paper. Circulation. 2004; 110: e572–e576.
|
Footnotes |
|---|
Guest Editor for this article was Kim Fox, MD.
Clinical trial registration information—URL: http://clinicaltrials.gov/ct/show. Unique identifier: NCT00000479.
This article has been cited by other articles:
 |
|
 |
|
  J. S. Danik, G. Pare, D. I. Chasman, R. Y.L. Zee, D. J. Kwiatkowski, A. Parker, J. P. Miletich, and P. M Ridker Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women: The Women's Genome Health Study Circ Cardiovasc Genet, April 1, 2009; 2(2): 134 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target? Clin. Chem., February 1, 2009; 55(2): 239 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, D. I. Chasman, R. Y.L. Zee, A. Parker, L. Rose, N. R. Cook, J. E Buring, and for the Women's Genome Health Study Working Group Rationale, Design, and Methodology of the Women's Genome Health Study: A Genome-Wide Association Study of More Than 25 000 Initially Healthy American Women Clin. Chem., February 1, 2008; 54(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, C. Bickel, V. Nicaud, R. Schnabel, H.J. Rupprecht, D. Peetz, K.J. Lackner, F. Cambien, S. Blankenberg, L. Tiret, et al. Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease: The AtheroGene Study Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2793 - 2799. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||